Trial reportNeuro-oncology2015
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Erratum issued Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00859222 (Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma), which is not on this map. Cited by 87 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Journal of the American Heart Association · 2017Pooled it
- A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma.Neuro-oncology · 2020Trial
- Dynamic regulation of H3K9 modifications in cancer: pathogenesis and targeted therapies.Biomarker research · 2026Review
- Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.Molecular therapy. Oncology · 2026Article
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models.iScience · 2026Article
- Co-delivery of panobinostat and siSTAT3 using engineered M1 exosomes to establish a one-two punch therapeutic strategy for glioblastoma recurrence.Materials today. Bio · 2026Article
- Acetylation modification in malignant progression and therapeutic resistance of gliomas.Frontiers in cell and developmental biology · 2026Review
- Targeting Survivin: Now I Become Death, the Destroyer of Cells.International journal of molecular sciences · 2025Review
- Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high-grade IDH mutant gliomas.JCI insight · 2025Article
- Neprilysin regulates the progression of glioblastoma: an in-vitro study using siRNA mediated gene silencing and HDAC1 mediated upregulation of neprilysin in U87 MG cells.Molecular and cellular biochemistry · 2025Article
- Article
- Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer.Current oncology (Toronto, Ont.) · 2025Review
- Post-translational modifications in DNA damage repair: mechanisms underlying temozolomide resistance in glioblastoma.Oncogene · 2025Review
- Epigenetic regulation of histone modifications in glioblastoma: recent advances and therapeutic insights.Biomarker research · 2025Review
- Review
- Central nervous system distributional kinetics of selected histone deacetylase inhibitors.The Journal of pharmacology and experimental therapeutics · 2025Article
- Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials.International journal of molecular sciences · 2024Review
- Review
- Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedErratum.2015
Authors and funding
20 authors at 7 institutions in 1 country.
Eudocia Q LeeDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
David A ReardonDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
David SchiffDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Jan DrappatzDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Alona MuzikanskyDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Sean A GrimmDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Andrew D NordenDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Lakshmi NayakDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Rameen BeroukhimDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Mikael L RinneDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Andrew S ChiDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Tracy T BatchelorDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Kelly HempflingDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Christine McCluskeyDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Katrina H SmithDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Sarah C GaffeyDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Brendan WrigleyDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Keith L LigonDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Jeffrey J RaizerDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Patrick Y WenDana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (E.Q.L., D.A.R., A.D.N., L.N., R.B., M.L.R., K.H., C.M., K.H.S., S.C.G., B.W., K.L.L., P.Y.W.); University of Virginia, Charlottesville, Virginia (D.S.); University of Pittsburgh, Pittsburgh, Pennsylvania (J.D.); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (A.S.C., T,T.B., A.M.); Central DuPage Hospital, Warrenville, Illinois (S.A.G.); Northwestern University, Chicago, Illinois (J.J.R.).
Central DuPage Hospital · USHarvard University · USDana-Farber Brigham Cancer Center · USNorthwestern University · USUniversity of Pittsburgh · USUniversity of Virginia · USMassachusetts General Hospital · US
Funding
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KEITH LLOYD LIGON · 2013 to 2026
$33.5MTransgenic Mouse and Biobank CoreP01CA095616 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2003 to 2012
$20.3MTherapeutic Opportunities for Pediatric AstrocytomaP01CA142536 · NCI · DANA-FARBER CANCER INST · PI SEGAL, ROSALIND A. · 2011 to 2015
$7.9MClinical and Molecular Studies of Novel Therapeutics in Malignant Brain TumorsK24CA125440 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BATCHELOR, TRACY T · 2007 to 2016
$1.9MNCI NIH HHS K24 CA125440NCI NIH HHS P01 CA095616NCI NIH HHS P01 CA142536NCI NIH HHS P50 CA165962
Abstract
backgroundPanobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically with bevacizumab. We conducted a multicenter phase II trial of panobinostat combined with bevacizumab in patients with recurrent high-grade glioma (HGG).
methodsPatients with recurrent HGG were treated with oral panobinostat 30 mg 3 times per week, every other week, in combination with bevacizumab 10 mg/kg every other week. The primary endpoint was a 6-month progression-fee survival (PFS6) rate for participants with recurrent glioblastoma (GBM). Patients with recurrent anaplastic glioma (AG) were evaluated as an exploratory arm of the study.
resultsAt interim analysis, the GBM arm did not meet criteria for continued accrual, and the GBM arm was closed. A total of 24 patients with GBM were accrued prior to closure. The PFS6 rate was 30.4% (95%, CI 12.4%-50.7%), median PFS was 5 months (range, 3-9 months), and median overall survival (OS) was 9 months (range, 6-19 months). Accrual in the AG arm continued to completion, and a total of 15 patients were enrolled. The PFS6 rate was 46.7% (range, 21%-73%), median PFS was 7 months (range, 2-10 months), and median OS was 17 months (range, 5 months-27 months).
conclusionsThis phase II study of panobinostat and bevacizumab in participants with recurrent GBM did not meet criteria for continued accrual, and the GBM cohort of the study was closed. Although it was reasonably well tolerated, the addition of panobinostat to bevacizumab did not significantly improve PFS6 compared with historical controls of bevacizumab monotherapy in either cohort.
Indexed as
AdultAgedAngiogenesis InhibitorsAntineoplastic AgentsBevacizumabBrain NeoplasmsDisease-Free SurvivalDrug Therapy, CombinationFemaleGlioblastomaHistone Deacetylase InhibitorsHumansHydroxamic AcidsIndolesKaplan-Meier EstimateMaleAngiogenesis InhibitorsAntineoplastic AgentsBevacizumabHistone Deacetylase InhibitorsHydroxamic AcidsIndolesPanobinostatanaplastic gliomaantiangiogenesis,bevacizumabglioblastomapanobinostat
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT00859222ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.